Management of Patients with Advanced Non-Small-Cell Lung Cancer and Performance Status 2
作者： Rogerio Lilenbaum
关键词: Non small cell 、 Oncology 、 Performance status 、 Lung cancer 、 Medicine 、 Clin oncol 、 Internal medicine
摘要:
springer.com
sci-hub.st 参考文章(26)
M Ando, Y Ando, Y Hasegawa, K Shimokata, H Minami, K Wakai, Y Ohno, S Sakai, Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer British Journal of Cancer. ,vol. 85, pp. 1634- 1639 ,(2001) , 10.1054/BJOC.2001.2162
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, C. Trask, E. Bessell, C. K. Connolly, J. Tobias, R. L. Souhami, Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life Journal of Clinical Oncology. ,vol. 17, pp. 3188- 3194 ,(1999) , 10.1200/JCO.1999.17.10.3188
M Paesmans, J P Sculier, P Libert, G Bureau, G Dabouis, J Thiriaux, J Michel, O Van Cutsem, R Sergysels, P Mommen, Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of Clinical Oncology. ,vol. 13, pp. 1221- 1230 ,(1995) , 10.1200/JCO.1995.13.5.1221
K S Albain, J J Crowley, M LeBlanc, R B Livingston, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology. ,vol. 9, pp. 1618- 1626 ,(1991) , 10.1200/JCO.1991.9.9.1618
A. E. Taylor, Ian N. Olver, Thileepan Sivanthan, Marianne Chi, Craig Purnell, Observer error in grading performance status in cancer patients Supportive Care in Cancer. ,vol. 7, pp. 332- 335 ,(1999) , 10.1007/S005200050271
Christopher J. Sweeney, Junming Zhu, Alan B. Sandler, Joan Schiller, Chandra P. Belani, Corey Langer, James Krook, David Harrington, David H. Johnson, Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma Cancer. ,vol. 92, pp. 2639- 2647 ,(2001) , 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
T. Le Chevalier, D. Brisgand, J.C. Soria, J.Y. Douillard, J.L. Pujol, P. Ruffie, V. Aberola, S. Cigolari, Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung Cancer Oncologist. ,vol. 6, pp. 8- 11 ,(2001) , 10.1634/THEONCOLOGIST.6-SUPPL_1-8
G. Buccheri, D. Ferrigno, M. Tamburini, Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. European Journal of Cancer. ,vol. 32, pp. 1135- 1141 ,(1996) , 10.1016/0959-8049(95)00664-8
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer Journal of the National Cancer Institute. ,vol. 65, pp. 25- 32 ,(1980) , 10.1093/JNCI/65.1.25